A case with glucagonoma syndrome--endocrine and metabolic studies.
The results of clinical endocrine and metabolic studies on a 57-year-old female with surgically and autopsy verified glucagonoma syndrome were presented. All of the clinical manifestations of glucagonoma syndrome so far reported in the literature were noted but there was no evidence indicating the presence of multiple endocrine adenomatosis. The plasma IRG level was always more than 20 times above the normal, and the IRG response to insulin and tolbutamide injection was abnormal and the results of the other endocrinological studies revealed less remarkable features, if any. The surgically removed metastatic tumor of the liver contained an enormous amount of IRG and an appreciable amount of IRI, indicating that the elevated plasma IRG was mainly of tumor origin. These results clearly indicate that in glucagonoma there is some abnormality in glucagon release from the tumor. In addition to these findings, hypocalcemia, cardiac left ventricular hypertrophy and gastrointestinal dysfunction reportedly due to hyperglucagonemia were also seen in this patient.
D007516:Adenoma, Islet Cell / Q000503:physiopathology*; D002096:C-Peptide / Q000097:blood; D004702:Endocrine Glands / Q000503:physiopathology; D005260:Female; D005934:Glucagon / Q000378:metabolism*; D005935:Glucagonoma / Q000378:metabolism / Q000503:physiopathology*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008113:Liver Neoplasms / Q000378:metabolism / Q000556:secondary; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000503:physiopathology*; D014044:Tolbutamide / Q000494:pharmacology
D002096:C-Peptide; D007328:Insulin; D005934:Glucagon; D014044:Tolbutamide